Cargando…
A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer
This study expands the understanding of the role of target therapy in improving survival of patients with mCRC based on real-world study results. These data represent potential survival outcomes of Taiwanese patients with mCRC in clinical practice. CRC is the most commonly diagnosed cancer and the t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968042/ https://www.ncbi.nlm.nih.gov/pubmed/35372058 http://dx.doi.org/10.3389/fonc.2022.808808 |
_version_ | 1784678961960189952 |
---|---|
author | Huang, Sheng-Chieh Lin, Chun-Chi Teng, Hao-Wei Lin, Hung-Hsin Chang, Shih-Ching Lan, Yuan-Tzu Wang, Huann-Sheng Yang, Shung-Haur Chen, Wei-Shone Jiang, Jeng-Kai |
author_facet | Huang, Sheng-Chieh Lin, Chun-Chi Teng, Hao-Wei Lin, Hung-Hsin Chang, Shih-Ching Lan, Yuan-Tzu Wang, Huann-Sheng Yang, Shung-Haur Chen, Wei-Shone Jiang, Jeng-Kai |
author_sort | Huang, Sheng-Chieh |
collection | PubMed |
description | This study expands the understanding of the role of target therapy in improving survival of patients with mCRC based on real-world study results. These data represent potential survival outcomes of Taiwanese patients with mCRC in clinical practice. CRC is the most commonly diagnosed cancer and the third leading cause of cancer-related death in Taiwan. The aim of this study was to evaluate the efficacy of target therapy in combination with chemotherapy for mCRC in Taiwan. This was a real-world, retrospective, observational study in patients diagnosed with mCRC (N=1583). A total of 792 patients received chemotherapy plus target therapy (anti-EGFR therapy, n=180; anti-VEGF therapy, n=612) and 791 patients who received chemotherapy alone. Overall survival (OS) and progression-free survival (PFS) were examined. For RAS wild-type patients, the median OS (mOS) was 34.3 months in the EGFR L (left-sided colon) group, 27.3 months in the VEGF L group, 18.4 months in VEGF R (right-sided colon) group, and 13.8 months in EGFR R group (P<0.001). Median PFS (mPFS) was 9.8 months in the EGFR L group, 8.9 months in the VEGF L group, 6.8 months in VEGF R group, and 5.8 months in EGFR R group. In patients with a RAS mutation, mOS was 25.4 months in the VEGF L group and 19.4 months in the VEGF R group (P=0.167). Judicious treatment allocation in Taiwanese patients with mCRC can result in an mOS of 34.3 months using cetuximab plus chemotherapy for left-sided tumors. An mOS of 48.5 months can be achieved using cetuximab plus chemotherapy in the neoadjuvant setting in mCRC patients with left-sided tumors. This study expands our understanding of the role of target therapy in improving survival of mCRC patients based on real-world study results. |
format | Online Article Text |
id | pubmed-8968042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89680422022-04-01 A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer Huang, Sheng-Chieh Lin, Chun-Chi Teng, Hao-Wei Lin, Hung-Hsin Chang, Shih-Ching Lan, Yuan-Tzu Wang, Huann-Sheng Yang, Shung-Haur Chen, Wei-Shone Jiang, Jeng-Kai Front Oncol Oncology This study expands the understanding of the role of target therapy in improving survival of patients with mCRC based on real-world study results. These data represent potential survival outcomes of Taiwanese patients with mCRC in clinical practice. CRC is the most commonly diagnosed cancer and the third leading cause of cancer-related death in Taiwan. The aim of this study was to evaluate the efficacy of target therapy in combination with chemotherapy for mCRC in Taiwan. This was a real-world, retrospective, observational study in patients diagnosed with mCRC (N=1583). A total of 792 patients received chemotherapy plus target therapy (anti-EGFR therapy, n=180; anti-VEGF therapy, n=612) and 791 patients who received chemotherapy alone. Overall survival (OS) and progression-free survival (PFS) were examined. For RAS wild-type patients, the median OS (mOS) was 34.3 months in the EGFR L (left-sided colon) group, 27.3 months in the VEGF L group, 18.4 months in VEGF R (right-sided colon) group, and 13.8 months in EGFR R group (P<0.001). Median PFS (mPFS) was 9.8 months in the EGFR L group, 8.9 months in the VEGF L group, 6.8 months in VEGF R group, and 5.8 months in EGFR R group. In patients with a RAS mutation, mOS was 25.4 months in the VEGF L group and 19.4 months in the VEGF R group (P=0.167). Judicious treatment allocation in Taiwanese patients with mCRC can result in an mOS of 34.3 months using cetuximab plus chemotherapy for left-sided tumors. An mOS of 48.5 months can be achieved using cetuximab plus chemotherapy in the neoadjuvant setting in mCRC patients with left-sided tumors. This study expands our understanding of the role of target therapy in improving survival of mCRC patients based on real-world study results. Frontiers Media S.A. 2022-03-17 /pmc/articles/PMC8968042/ /pubmed/35372058 http://dx.doi.org/10.3389/fonc.2022.808808 Text en Copyright © 2022 Huang, Lin, Teng, Lin, Chang, Lan, Wang, Yang, Chen and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Huang, Sheng-Chieh Lin, Chun-Chi Teng, Hao-Wei Lin, Hung-Hsin Chang, Shih-Ching Lan, Yuan-Tzu Wang, Huann-Sheng Yang, Shung-Haur Chen, Wei-Shone Jiang, Jeng-Kai A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer |
title | A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer |
title_full | A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer |
title_fullStr | A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer |
title_full_unstemmed | A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer |
title_short | A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer |
title_sort | long-term and large-scale real-world study in taiwan: efficacy of target therapy in stage iv colorectal cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968042/ https://www.ncbi.nlm.nih.gov/pubmed/35372058 http://dx.doi.org/10.3389/fonc.2022.808808 |
work_keys_str_mv | AT huangshengchieh alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT linchunchi alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT tenghaowei alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT linhunghsin alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT changshihching alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT lanyuantzu alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT wanghuannsheng alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT yangshunghaur alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT chenweishone alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT jiangjengkai alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT huangshengchieh longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT linchunchi longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT tenghaowei longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT linhunghsin longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT changshihching longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT lanyuantzu longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT wanghuannsheng longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT yangshunghaur longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT chenweishone longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT jiangjengkai longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer |